5 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow Xiaoxiang Chen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Variance of HRD From Paired Ovarian Cancer Ovarian Cancer, HRD | Unknown | Xiaoxiang Chen | 50 | 2021-10-01 | 2021-10-06 | |
| Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients PARP inhibitor - Ovarian Cancer, HRD | Unknown | Xiaoxiang Chen | 100 | 2021-09-15 | 2021-09-14 | |
| The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer PARP inhibitors - Ovarian Cancer, Clinical Marker | Unknown | Xiaoxiang Chen | 60 | 2020-12-15 | 2021-01-20 | |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Niraparib, Bevacizumab - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 32 | 2020-11-06 | 2020-11-10 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Anlotinib, Olaparib - Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 68 | 2020-10-28 | 2020-10-30 |
Ovarian Neoplasms (5) · Adnexal Diseases (2) · Carcinoma (2) · Carcinoma, Ovarian Epithelial (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Ovarian Diseases (2) · Urogenital Neoplasms (2) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Neoplasms (1)
niraparib (3) · olaparib (3) · Poly(ADP-ribose) Polymerase Inhibitors (2) · Bevacizumab (1) · anlotinib (1)
China (5)
Jing Ni, MD (1) · Xiaoxiang Chen Chen, MD,PhD (1)